HKD 3.31
(-2.93%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 2.11 Billion HKD | 11.41% |
2022 | 1.85 Billion HKD | 33.7% |
2021 | 1.39 Billion HKD | 28.78% |
2020 | 1.09 Billion HKD | -33.87% |
2019 | 1.69 Billion HKD | 9.68% |
2018 | 1.38 Billion HKD | 25.54% |
2017 | 1.11 Billion HKD | 21.74% |
2016 | 906.13 Million HKD | 20.7% |
2015 | 750.75 Million HKD | -2.97% |
2014 | 785.37 Million HKD | 12.61% |
2013 | 689.46 Million HKD | 32.43% |
2012 | 522.18 Million HKD | 279.65% |
2011 | 140.63 Million HKD | -68.44% |
2010 | 434.32 Million HKD | 14.71% |
2009 | 377.35 Million HKD | 70.3% |
2008 | 221.69 Million HKD | 29.5% |
2007 | 171.19 Million HKD | 76.75% |
2006 | 129.81 Million HKD | -26.23% |
2005 | 131.28 Million HKD | 2.54% |
2004 | 128.03 Million HKD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 1.08 Billion HKD | 0.0% |
2023 Q2 | 945.28 Million HKD | 0.0% |
2023 Q4 | 950.43 Million HKD | 0.0% |
2023 FY | - HKD | 11.41% |
2022 Q4 | 803.92 Million HKD | 0.0% |
2022 FY | - HKD | 33.7% |
2022 Q2 | 925.67 Million HKD | 0.0% |
2021 Q4 | 781.52 Million HKD | 0.0% |
2021 Q2 | 512.08 Million HKD | 0.0% |
2021 FY | - HKD | 28.78% |
2020 Q4 | 582.43 Million HKD | 0.0% |
2020 Q2 | 422.08 Million HKD | 0.0% |
2020 FY | - HKD | -33.87% |
2019 FY | - HKD | 9.68% |
2019 Q2 | 802.07 Million HKD | 0.0% |
2019 Q4 | 708.04 Million HKD | 0.0% |
2018 Q4 | 699.07 Million HKD | 0.0% |
2018 FY | - HKD | 25.54% |
2018 Q2 | 685.85 Million HKD | 0.0% |
2017 Q2 | 498.39 Million HKD | 0.0% |
2017 FY | - HKD | 21.74% |
2017 Q4 | 604.75 Million HKD | 0.0% |
2016 Q4 | 473.99 Million HKD | 0.0% |
2016 Q2 | 432.14 Million HKD | 0.0% |
2016 FY | - HKD | 20.7% |
2015 FY | - HKD | -2.97% |
2015 Q4 | 335.95 Million HKD | 0.0% |
2015 Q2 | 414.8 Million HKD | 0.0% |
2014 Q2 | 410.39 Million HKD | 0.0% |
2014 Q4 | 363.36 Million HKD | 0.0% |
2014 FY | - HKD | 12.61% |
2013 Q3 | 172.36 Million HKD | -52.74% |
2013 FY | - HKD | 32.43% |
2013 Q4 | 232.25 Million HKD | 34.75% |
2013 Q2 | 364.74 Million HKD | 111.62% |
2013 Q1 | 172.36 Million HKD | 0.0% |
2012 Q4 | 172.36 Million HKD | 32.35% |
2012 Q1 | 130.23 Million HKD | 0.0% |
2012 FY | - HKD | 279.65% |
2012 Q2 | 130.23 Million HKD | 0.0% |
2012 Q3 | 130.23 Million HKD | 0.0% |
2011 Q3 | 34.16 Million HKD | 0.0% |
2011 Q2 | 34.16 Million HKD | 0.0% |
2011 Q1 | 34.16 Million HKD | 0.0% |
2011 FY | - HKD | -68.44% |
2011 Q4 | 130.23 Million HKD | 281.24% |
2010 FY | - HKD | 14.71% |
2010 Q4 | 34.16 Million HKD | -68.44% |
2010 Q1 | 108.25 Million HKD | 0.0% |
2010 Q3 | 108.25 Million HKD | 0.0% |
2010 Q2 | 108.25 Million HKD | 0.0% |
2009 Q4 | 108.25 Million HKD | 14.72% |
2009 Q2 | 94.36 Million HKD | 0.0% |
2009 Q1 | 94.36 Million HKD | 0.0% |
2009 FY | - HKD | 70.3% |
2009 Q3 | 94.36 Million HKD | 0.0% |
2008 Q4 | 94.36 Million HKD | 70.33% |
2008 FY | - HKD | 29.5% |
2008 Q3 | 55.4 Million HKD | 0.0% |
2008 Q2 | 55.4 Million HKD | 0.0% |
2008 Q1 | 55.4 Million HKD | 0.0% |
2007 Q4 | 55.4 Million HKD | 29.47% |
2007 FY | - HKD | 76.75% |
2007 Q2 | 42.79 Million HKD | 0.0% |
2007 Q1 | 42.79 Million HKD | 0.0% |
2007 Q3 | 42.79 Million HKD | 0.0% |
2006 Q1 | 23.03 Million HKD | 0.0% |
2006 Q4 | 42.79 Million HKD | 85.74% |
2006 FY | - HKD | -26.23% |
2006 Q3 | 23.03 Million HKD | 0.0% |
2006 Q2 | 23.03 Million HKD | 0.0% |
2005 Q3 | 31.62 Million HKD | 0.0% |
2005 Q1 | 31.62 Million HKD | 0.0% |
2005 FY | - HKD | 2.54% |
2005 Q2 | 31.62 Million HKD | 0.0% |
2005 Q4 | 23.03 Million HKD | -27.15% |
2004 FY | - HKD | 0.0% |
2004 Q1 | 30.83 Million HKD | 0.0% |
2004 Q2 | 30.83 Million HKD | 0.0% |
2004 Q3 | 30.83 Million HKD | 0.0% |
2004 Q4 | 31.62 Million HKD | 2.56% |
2003 Q4 | 30.83 Million HKD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Pak Fah Yeow International Limited | 150.4 Million HKD | -1305.955% |
Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 28.72% |
Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 1732.61% |
Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -1758.166% |
Qianhai Health Holdings Limited | -50.22 Million HKD | 4309.831% |
Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -1825.474% |
Essex Bio-Technology Limited | 418.37 Million HKD | -405.419% |
Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -2659.328% |
PuraPharm Corporation Limited | -26.16 Million HKD | 8180.385% |
JBM (Healthcare) Limited | 204.39 Million HKD | -934.569% |
Jacobson Pharma Corporation Limited | 429.92 Million HKD | -391.848% |
China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 86.297% |